Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study

Lihua E Budde ,Pratyush Giri,Matthew Ku,Sascha Dietrich,Matthew J Matasar,Keith Fay,Nancy L Bartlett,John Kuruvilla,Sarit Assouline,Laurie H Sehn,Shen Yin,Michael C Wei,Elicia Penuel,Raluca Negricea,Miguel Canales,Stephen J Schuster,Huang Huang,Michelle Y Doral,Carol O’hear ,Loretta J Nastoupil ,Chi‐Chung Li

doi:10.1182/blood-2021-145872

Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study

Lihua E Budde , Pratyush Giri + Show 19 more

Open Access

https://doi.org/10.1182/blood-2021-145872

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2021
Citations: 22

Affiliation: City of Hope, Royal Adelaide Hospital, University of Melbourne, St Vincent's Hospital, Heidelberg University, Memorial Sloan Kettering Cancer Center, Royal North Shore Hospital, Washington University in St. Louis, Princess Margaret Cancer Centre, Jewish General Hospital, University of British Columbia, Spinal Cord Injury BC, Roche (United Kingdom), Hospital Universitario La Paz, UPMC Hillman Cancer Center, University of Pennsylvania, Roche (Canada), The University of Texas MD Anderson Cancer Center

#Equity Holder In Publicly-traded Company #Research Funding + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.